NCT05390424 Screening for Hepatitis B, Hepatitis C and AIDS Viruses Using Dried Blood Spot
| NCT ID | NCT05390424 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Rouen |
| Condition | Hepatitis B |
| Study Type | INTERVENTIONAL |
| Enrollment | 500 participants |
| Start Date | 2022-12-02 |
| Primary Completion | 2027-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 500 participants in total. It began in 2022-12-02 with a primary completion date of 2027-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of the study is to screen for hepatitis B, hepatitis C and AIDS viruses using a Dried Blood Spot in drug users
Eligibility Criteria
Inclusion Criteria: * Former or active intravenous and/or nasal drug user * Person on opiate substitution therapy Exclusion Criteria: * Person with known active viral infection(s)
Contact & Investigator
Ghassan RIACHI, MD
PRINCIPAL INVESTIGATOR
University Hospital, Rouen
Frequently Asked Questions
Who can join the NCT05390424 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hepatitis B. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05390424 currently recruiting?
Yes, NCT05390424 is actively recruiting participants. Contact the research team at ghassan.riachi@chu-rouen.fr for enrollment information.
Where is the NCT05390424 trial being conducted?
This trial is being conducted at Avranches, France, Barentin, France, Dieppe, France, Elbeuf, France and 7 additional locations.
Who is sponsoring the NCT05390424 clinical trial?
NCT05390424 is sponsored by University Hospital, Rouen. The principal investigator is Ghassan RIACHI, MD at University Hospital, Rouen. The trial plans to enroll 500 participants.